Mechanism of Taohong Siwu Decoction in Treating Postmenopausal Osteoporosis of Kidney Deficiency and Blood Stasis Based on Network Pharmacology and Molecular Docking Technology
CAI Weiliang, CAI Anlie
Department of Orthopaedic, The Second Xiangya Hospital of Central South University, Changsha Hunan 410011
Abstract：【Objective】To investigate the mechanism of Taohong Siwu decoction in the treatment of postmenopausal osteoporosis (PMOP) based on network pharmacology and molecular docking technology. 【Methods】The active ingredients and potential targets of Taohong Siwu decoction were obtained through the screening of Traditional Chinese Medicine (TCM) System Pharmacology database and its analysis llatform (TCMSP) database. The core targets of its treatment were determined by combining the target mining results of multiple databases. And the complex relationship among targets was constructed by PPI network analysis. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and gene ontology (GO) function analysis were performed using R4.1.2; Then key active ingredients were docked with core targets.【Results】 There were 285 active components in Taohong Siwu decoction. The advanced glycosylated end-product-receptor Pathway (AGE-RAGE signaling pathway), TNF signaling pathway and hypoxic-inducible factor receptor pathway (HIF-1 signaling pathway) were involved in Taohong Siwu decoction therapy. Molecular docking analysis showed that luteolin was well bound to interleukin-6 (IL-6), while quercetin had good binding properties with RUNt-associated transcription factor 2 (RUNX2) macromolecular proteins.【Conclusion】The therapeutic effect of Taohong Siwu decoction on PMOP with kidney deficiency and blood stasis involves several key active ingredients, multiple action targets and core signaling pathways. It provides a new perspective and idea for the mechanism of treating PMOP with kidney deficiency and blood stasis.
蔡伟良, 蔡安烈. 桃红四物汤治疗肾虚血瘀型绝经后骨质疏松症的基于网络药理学和分子对接技术的作用机制*[J]. 医学临床研究, 2024, 41(9): 1297-1300.
CAI Weiliang, CAI Anlie. Mechanism of Taohong Siwu Decoction in Treating Postmenopausal Osteoporosis of Kidney Deficiency and Blood Stasis Based on Network Pharmacology and Molecular Docking Technology. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1297-1300.
[1] XU Q, LI D, CHEN J, et al. Crosstalk between the gut microbiota and postmenopausal osteoporosis:mechanisms and applications[J].Int Immunopharmacol,2022,110:108998.
[2] 苏俊, 朱旭红, 张治芬. “治未病”理论在围绝经期及绝经后女性骨质疏松症互联网+健康管理中的研究进展[J].中国医药科学,2024,14(9):40-44.
[3] KOBAYAKAWA T, MIYAZAKI A, SAITO M, et al. Denosumab versus romosozumab for postmenopausal osteoporosis treatment[J].Sci Rep,2021,11(1):11801.
[4] 贾元霞, 郭雪梅, 傅巧霞,等. 绝经后骨质疏松症的中医病机认识及治疗进展[J].中医临床研究,2024,16(3):101-103.
[5] 张宁, 董一平, 袁强,等. 中医药通过作用破骨细胞调控治疗绝经后骨质疏松研究进展[J].陕西中医,2024,45(1):136-138.
[6] 谢林,姚共和,郭振球,等.健脾养胃法治疗骨质疏松症初探[J].湖南中医学院学报,1996,16(4):7-9.
[7] 李汪洋, 熊辉. 桃红四物汤早期干预对大鼠骨折愈合中间充质干细胞归巢的影响[J].中国骨伤,2022,35(4):367-374.
[8] 张娴, 徐志红, 陈磊垚,等. 桃红四物汤对维甲酸诱导大鼠骨质疏松的干预作用[J].安徽医药,2023,27(8):1502-1506.
[9] 谭思敏, 陈文辉, 李双蕾,等. 中医药治疗绝经后骨质疏松症的研究进展[J].大众科技,2022,24(10):71-74.
[10] 孙传睿, 李秋月, 金子开,等. 中医药调控肠道菌群治疗绝经后骨质疏松症的研究进展[J].中国骨质疏松杂志,2023,29(5):739-744.
[11] 王永刚, 王蛟龙. 桃红四物汤临床研究进展[J].基层中医药,2023,2(11):99-105.
[12] 薛玲, 潘洋, 郑伟. 浅析桃红四物汤的临床应用及研究进展[J].光明中医,2022,37(15):2861-2864.
[13] 向雨婷, 石立鹏, 杜旭勤,等. 桃红四物汤治疗心血管疾病的基础与临床研究进展[J].湖南中医杂志,2021,37(5):179-181.
[14] 陈琛洁, 潘汉升, 蒋彧轩,等. 桃红四物汤在骨伤科的临床应用与实验研究进展[J].中医临床研究,2021,13(9):129-132.
[15] 聂欣, 成颜芬, 王琳,等. 桃红四物汤化学成分、药理作用、临床应用的研究进展及质量标志物的预测分析[J].中国实验方剂学杂志,2020,26(4):226-234.
[16] 杨治, 张亚楠. 桃红四物汤治疗冠心病的临床运用及机制研究进展[J].辽宁中医杂志,2023,50(2):209-212.
[17] ZHENG H L, XU W N, ZHOU W S, et al. Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced RUNX2 ubiquitination[J].Cell Death Dis,2021,12(5):497.
[18] VITA F, GANGEMI S, PIOGGIA G, et al. Physical activity and post-transcriptional regulation of aging decay:modulation of pathways in postmenopausal osteoporosis[J].Medicina (Kaunas), 2022,58(6):767.
[19] YU T, YOU X M, ZHOU H C, et al. MiR-16-5p regulates postmenopausal osteoporosis by directly targeting VEGFA[J].Aging (Albany NY),2020,12(10):9500-9514.
[20] WANG Z Y, GE X H, WANG Y, et al. Mechanism of dexmedetomidine regulating osteogenesis-angiogenesis coupling through the miR-361-5p/VEGFA axis in postmenopausal osteoporosis[J]. Life Sci,2021,275:119273.
[21] 田佳庆, 韦雨柔, 肖方骏,等. 虎杖苷调控HIF-1α/VEGF信号通路对绝经后骨质疏松症大鼠H型血管生成的影响[J].中成药,2024,46(5):1672-1676.
[22] WANG T T, HE C Q. TNF-α and IL-6:the link between immune and bone system[J].Curr Drug Targets,2020,21(3):213-227.
[23] CHENG C H, CHEN L R, CHEN K H. Osteoporosis due to hormone imbalance:an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover[J].Int J Mol Sci,2022,23(3):1376.
[24] WANG Y, CHE L B, CHEN X, et al. Repurpose dasatinib and quercetin:Targeting senescent cells ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration[J].Bioact Mater,2023,25:13-28.
[25] 许勇, 谢贤斐, 颜威,等. 木犀草素调控PI3K/AKT通路改善绝经后骨质疏松症大鼠模型骨丢失的机制[J].热带医学杂志,2022,22(5):639-643.
[26] HUANG C C, LI Y, LI B, et al. Identifying potential ferroptosis key genes for diagnosis and treatment of postmenopausal osteoporosis through competitive endogenous RNA network analysis[J].Heliyon,2024,10(1):e23672.
[27] CHEN W, WU P F, YU F, et al. HIF-1α regulates bone homeostasis and angiogenesis, participating in the occurrence of bone metabolic diseases[J].Cells,2022,11(22):3552.
2024, Vol. 41 
